Research programme: eye disorder therapeutics - Janssen Pharmaceuticals/University of Massachusetts
Latest Information Update: 10 Jan 2017
At a glance
- Originator University of Massachusetts Amherst
- Developer Janssen Pharmaceuticals; University of Massachusetts Amherst
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders